SAN DIEGO, January 20, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), and Regen have entered into a formal research collaboration agreement to jointly explore the biology of the NR2F6 protein.
Specifically, the collaboration will focus on identifying ligands for the nuclear receptor NR2F6 using Regen’s patented screening methodology and the sophisticated expertise and unique chemical libraries of NCATS. A ligand is a substance that forms a complex with a biomolecule to serve a biological purpose.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists and antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient’s own immune system.
“Regen is entering into a new phase as it is now both a clinical stage company and one with a promising pipeline of research,” said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen Biopharma. “One of our goals for 2016 is to rapidly move our small molecule screening program forward, and collaborating with world experts in this field is part of our strategy. Our collaborator at NCATS, Dr. Menghang Xia is a research scientist with vast experience in assay development, compound screening and probe/ligand identification.”
“We have a very defined, strategic implementation plan for 2016 and we have every intention of executing it successfully,” said David Koos, Ph.D., Chairman and CEO of Regen. “This screening program, which is growing quickly, is an important element to our strategy of developing a novel checkpoint inhibitor.”
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
The Dorsee Company
Debra Dorsee
+1-(858)229-6082
Debbie@thedorseecompany.com
http://www.regenbiopharma.com and http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/KoosRegen
SOURCE Regen BioPharma Inc.
